Biosimilars Dodge State Roadblocks, But Big Hurdles Remain
The once-promising biosimilars industry is finally getting some good news as state lawmakers largely balk at bills designed to curtail access to the cheaper versions of pricey brand-name biologic drugs, but...To view the full article, register now.
Already a subscriber? Click here to view full article